Business, energy, technology, markets and global industry news from Business News Today

biologics

PharmaDeviceNews biologics
Representative image: A biotech laboratory scene showing injectable biologic formulation work, reflecting how the Halozyme Therapeutics and Oruka Therapeutics Hypercon agreement could shape the next phase of long-acting psoriasis drug delivery.
Pharma & Biotech

Why Halozyme’s Hypercon deal with Oruka could matter beyond one psoriasis antibody

Psoriasis biologics are getting longer acting. Halozyme and Oruka now face the harder test of making high-dose therapy practical.

Read More
Representative image: Mabwell’s 9MW5211 FDA clearance highlights growing clinical interest in first-in-class antibody therapies for inflammatory bowel disease, as biotech developers target pathogenic immune cells to reshape autoimmune disease treatment.
Pharma & Biotech

Mabwell’s 9MW5211 gets FDA clearance, but can a first-in-class autoimmune antibody break through?

Mabwell has FDA clearance for 9MW5211. The bigger test is whether a first-in-class autoimmune antibody can prove durable remission.

Read More
Pharma & Biotech

What Biomolecular Holdings LLC’s platform patents reveal about the future of antibody engineering

Biomolecular Holdings LLC secures platform patents for tetrahedral antibodies. Discover what this means for the future of antibody engineering.

Read More
Pharma & Biotech

Tivic Health Systems becomes Valion Bio but the real story lies in its biodefense pivot

Valion Bio’s pivot to biodefense and oncology could reshape biotech funding. Find out what this transformation means for investors and the industry.

Read More
Representative image of alopecia areata research as Nektar Therapeutics prepares to discuss 52-week REZOLVE-AA Phase 2b topline results for rezpegaldesleukin in severe-to-very-severe alopecia areata.
Pharma & Biotech

Can Nektar’s 52-week REZOLVE-AA update strengthen the case for rezpegaldesleukin in alopecia areata?

Nektar will discuss 52-week REZOLVE-AA data for rezpegaldesleukin on April 20. Find out what the alopecia areata catalyst could mean.

Read More
Representative image of an atopic dermatitis drug development concept, illustrating how Zai Lab’s ZL-1503 is being positioned to target itch and inflammation pathways in early-stage immunology research.
Pharma & Biotech

Can Zai Lab’s ZL-1503 turn dual-pathway itch control into a real atopic dermatitis advantage?

Zai Lab’s ZL-1503 showed durable preclinical itch and inflammation control. Read what its 2026 clinical path could mean for atopic dermatitis.

Read More
Pharma & Biotech

Why CUE-401’s IMMUNOLOGY2026 data could matter for autoimmune drug pipelines

Cue Biopharma, Inc. unveils new CUE-401 data. Find out what this means for autoimmune therapy development and the regulatory path ahead.

Read More
Pharma & Biotech

Could Hinge Bio, Inc. unlock a new class of lupus B-cell depletion therapies?

Hinge Bio, Inc. doses first subjects in HB2198 Phase 1 trial. Discover what this could mean for lupus treatment and next-generation immune reset therapies.

Read More
Pharma & Biotech

Why the latest Merakris Therapeutics data may sharpen industry focus on refractory wound healing

Read why Merakris Therapeutics’ MTX-001 data may sharpen industry focus on refractory wound healing and reshape the late-stage wound care outlook.

Read More
Representative image of a child undergoing a dermatology skin examination, illustrating the growing focus on pediatric eczema treatment as Galderma’s nemolizumab phase II data sharpen competition in the biologic landscape for atopic dermatitis.
Pharma & Biotech

What Galderma’s nemolizumab phase II data mean for the competitive biologic landscape in pediatric eczema

Galderma's nemolizumab phase II data in children aged 2-11 show 52-week itch and lesion relief. Read the analysis.

Read More